ChinaBio(R) LLC Release: China Announces Another Round of Drug Price Cuts

Published: Sep 21, 2012

by Henry Ye and Richard Daverman, PhD

September 20, 2012 -- In a widely expected move, China ordered an average 17% reduction in the maximum retail prices of 95 cancer, immunology and blood-related drugs, many of them produced by foreign drugmakers. Unlike earlier rounds of price cuts, this one concentrated on drugs with high daily costs. Especially hard hit were drugs with “separated pricing” – the drugs available from a foreign manufacturer at a higher price than their China generic equivalents. At the same time, China’s NDRC reiterated support for prices that are high enough to encourage innovative drug research. More details....

Back to news